Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity.

Caputo M, Daffara T, Bellone S, Mancioppi V, Marzullo P, Aimaretti G, Prodam F

Frontiers in endocrinology22 Jun 2021Cited by 1 (Europe PMC)

PMID34239499PMCIDPMC8258411DOI10.3389/fendo.2021.687918PepBankPUB-34239499

Summary

Genetic obesity, including syndromic and non-syndromic forms, represents a minority of cases compared to essential obesity but gene dysregulations lead to complex clinical conditions that make their management particularly difficult. Among them, Beckwith-Wiedemann syndrome (BWS) is a multisystem human genomic imprinting disorder characterized by overgrowth. We describe the first case of liraglutide treatment in an 18-year-old boy patient affected by BWS complicated by macroglossia, cryptorchidism, nephroblastoma, organomegaly, microscopic lymphocytic colitis, pharmacologically treated arterial hypertension, obesity, and obstructive sleep apnea syndrome. He presented a normal cognitive development. Body mass index at the time of first transition visit in the adult endocrinology department at the age of 18-years-old was 40.6 kg/m² without glucose metabolism impairment. Lifestyle interventions failed because of poor compliance. During 20 months of 3.0 mg liraglutide treatment, a weight loss of 19 kg (-13.3%) and BMI reduction of 6.8 points were registered without side effects. To date, liraglutide treatment was effective on obesity in 7 subjects with Prader Willy Syndrome and 14 with melanocortin-4 receptor mutations. The efficacy of liraglutide in BWS could be related to a crosstalk among glucagon-like peptide (GLP)-1 system, mechanisms related to the cyclin-dependent kinase inhibitor 1C (CDKN1C), and dopamine mesolimbic circuit. Clinical trials aiming at a tailored medicine in genetic obesity are needed.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanCase report or seriesEfficacy outcome
In an 18-year-old with Beckwith-Wiedemann syndrome and obesity, 20 months of liraglutide 3.0 mg reduced body weight by 19 kg (-13.3%).
In plain wordsIn one young man with Beckwith-Wiedemann syndrome and obesity, liraglutide for 20 months was followed by a 19 kg weight loss.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 20 monthsAs given in this study (human).
Measurements
Weight change
−19 kg
20 months
Weight change
−13.3%
20 months
Source sentences
Summary
During 20 months of 3.0 mg liraglutide treatment, a weight loss of 19 kg (-13.3%)
1 context sentence(design, population, supporting numbers)
Summary · context
We describe the first case of liraglutide treatment in an 18-year-old boy patient affected by BWS complicated by macroglossia, cryptorchidism, nephroblastoma, organomegaly, microscopic lymphocytic colitis, pharmacologically treated arterial hypertension, obesity, and obstructive sleep apnea syndrome.
Show in the study text Report a problemFND-3423949901
02HumanCase report or seriesEfficacy outcome
In an 18-year-old with Beckwith-Wiedemann syndrome and obesity, 20 months of liraglutide 3.0 mg reduced BMI by 6.8 points.
In plain wordsIn one young man with Beckwith-Wiedemann syndrome and obesity, liraglutide for 20 months was followed by a 6.8 point drop in BMI.
Peptide
Liraglutide
Outcome
DecreaseBMI reduction
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 20 monthsAs given in this study (human).
Measurements
BMI reduction
6.8 points
20 months
Source sentences
Summary
During 20 months of 3.0 mg liraglutide treatment, a weight loss of 19 kg (-13.3%) and BMI reduction of 6.8 points
1 context sentence(design, population, supporting numbers)
Summary · context
We describe the first case of liraglutide treatment in an 18-year-old boy patient affected by BWS complicated by macroglossia, cryptorchidism, nephroblastoma, organomegaly, microscopic lymphocytic colitis, pharmacologically treated arterial hypertension, obesity, and obstructive sleep apnea syndrome.
Show in the study text Report a problemFND-3423949902
03HumanCase report or seriesSafety outcome
In an 18-year-old with Beckwith-Wiedemann syndrome and obesity, no side effects were registered during 20 months of liraglutide 3.0 mg.
In plain wordsIn one young man with Beckwith-Wiedemann syndrome, no side effects were recorded during 20 months of liraglutide.
Peptide
Liraglutide
Outcome
No significant changeSide effects
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
3.0 mg · 20 monthsAs given in this study (human).
Source sentences
Summary
During 20 months of 3.0 mg liraglutide treatment, a weight loss of 19 kg (-13.3%) and BMI reduction of 6.8 points were registered without side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
We describe the first case of liraglutide treatment in an 18-year-old boy patient affected by BWS complicated by macroglossia, cryptorchidism, nephroblastoma, organomegaly, microscopic lymphocytic colitis, pharmacologically treated arterial hypertension, obesity, and obstructive sleep apnea syndrome.
Show in the study text Report a problemFND-3423949903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.